Last reviewed · How we verify

Angde Biotech Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Angde Biotech Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Recombinant human tissue plasminogen activator Recombinant human tissue plasminogen activator phase 3 Fibrinolytic agent / Thrombolytic Plasminogen / Fibrin Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. All India Institute of Medical Sciences · 1 shared drug class
  2. Beijing Chao Yang Hospital · 1 shared drug class
  3. Beijing Tiantan Hospital · 1 shared drug class
  4. Life Recovery Systems · 1 shared drug class
  5. Tasly Biopharmaceuticals Co., Ltd. · 1 shared drug class
  6. The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class
  7. Thrombolex, Inc. · 1 shared drug class
  8. Tianjin Huanhu Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Angde Biotech Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Angde Biotech Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/angde-biotech-pharmaceutical-co-ltd. Accessed 2026-05-16.

Related